Sequent Scientific Limited
Sequent Scientific Limited Fundamental Analysis
Sequent Scientific Limited (SEQUENT.NS) shows weak financial fundamentals with a PE ratio of 120.94, profit margin of 2.52%, and ROE of 5.53%. The company generates $16.6B in annual revenue with strong year-over-year growth of 13.55%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 44.4/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze SEQUENT.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakSEQUENT.NS struggles to generate sufficient returns from assets.
Valuation Score
WeakSEQUENT.NS trades at a premium to fair value.
Growth Score
ModerateSEQUENT.NS shows steady but slowing expansion.
Financial Health Score
ExcellentSEQUENT.NS maintains a strong and stable balance sheet.
Profitability Score
WeakSEQUENT.NS struggles to sustain strong margins.
Key Financial Metrics
Is SEQUENT.NS Expensive or Cheap?
P/E Ratio
SEQUENT.NS trades at 120.94 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, SEQUENT.NS's PEG of 3.00 indicates potential overvaluation.
Price to Book
The market values Sequent Scientific Limited at 6.25 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 23.53 times EBITDA. This signals the market has high growth expectations.
How Well Does SEQUENT.NS Make Money?
Net Profit Margin
For every $100 in sales, Sequent Scientific Limited keeps $2.52 as profit after all expenses.
Operating Margin
Core operations generate 13.06 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $5.53 in profit for every $100 of shareholder equity.
ROA
Sequent Scientific Limited generates $2.42 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Sequent Scientific Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Sequent Scientific Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
SEQUENT.NS converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
120.94
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
3.00
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.25
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.05
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.61
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.91
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.06
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.18
vs 25 benchmark
How SEQUENT.NS Stacks Against Its Sector Peers
| Metric | SEQUENT.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 120.94 | 29.45 | Worse (Expensive) |
| ROE | 5.53% | 779.00% | Weak |
| Net Margin | 2.52% | -24936.00% (disorted) | Weak |
| Debt/Equity | 0.61 | 0.26 | Weak (High Leverage) |
| Current Ratio | 1.91 | 4.65 | Neutral |
| ROA | 2.42% | -19344.00% (disorted) | Weak |
SEQUENT.NS outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Sequent Scientific Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
26.42%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-70.40%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-31.64%
Industry Style: Defensive, Growth, Innovation
Declining